Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03833427 · ClinicalTrials.gov registry record · Phase 1
Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Terminated
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT03833427 is a Phase 1 study that was terminated before completion, run by Merck Sharp & Dohme. The registered enrollment target is 32 participants.
The verdict
NCT03833427, a Phase 1 study, was terminated before completion, sponsored by Merck Sharp & Dohme.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study will examine the safety, pharmacokinetics, and efficacy of escalating doses of selumetinib (MK-5618) in combination with intravenous (IV) pembrolizumab (MK-3475) for participants with advanced / metastatic solid tumors.
Interventions
- DRUG Pembrolizumab
- DRUG Selumetinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2019-03-18 |
| Est. Completion | 2022-06-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03833427
The ClinicalTrials.gov registry entry for NCT03833427 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03833427 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03833427 about?
NCT03833427 is a clinical study titled "Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)". This study will examine the safety, pharmacokinetics, and efficacy of escalating doses of selumetinib (MK-5618) in combination with intravenous (IV) pembrolizumab (MK-3475) for participants with advanced / metastatic solid tumors.
What is the current status of trial NCT03833427?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2019-03-18. Estimated completion is 2022-06-28.
What interventions are being tested in trial NCT03833427?
The interventions under investigation include: Pembrolizumab (DRUG), Selumetinib (DRUG).
Who is sponsoring clinical trial NCT03833427?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.